Pre-chemotherapy drug sensitivity test for antitubercular drugs in India – is it essential? Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005
Do we need new antibiotics? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009
Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios Source: Eur Respir J 2015; 45: 25-29 Year: 2015
Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis Source: Eur Respir J, 54 (5) 1901381; 10.1183/13993003.01381-2019 Year: 2019
Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012
Compassionate use of bedaquiline in a cohort of Indian drug resistant tuberculosis(DR-TB) patients Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Long term macrolide antibiotics for the treatment of bronchiectasis in adults - individual participant data meta-analysis Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019
Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012
Second-line injectables: are they essential to treat MDR/XDR-TB cases? Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008
Efficacy and safety of new drugs for M/XDR-TB: what have we learned from observational studies? Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019
How patients use inhalers - what are the critical errors? Source: International Congress 2017 – Advances in Inhaler technology - intuitive design and better drug delivery Year: 2017
Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones}, Source: Eur Respir J 2012; 40: 814-822 Year: 2012
Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin Source: Eur Respir J, 55 (5) 1901903; 10.1183/13993003.01903-2019 Year: 2020
An audit of adherence to antituberculous drugs using a new, rapid, point of care test for isoniazid metabolites Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002
Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses Source: Eur Respir J, 50 (1) 1700061; 10.1183/13993003.00061-2017 Year: 2017
Should severe CAP patients receive anti-MRSA coverage? Pro argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017
SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß2 -agonist use in asthma Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019 Year: 2020
Respiratory medicines for children: current evidence, unlicensed use and research priorities Source: Eur Respir J 2010; 35: 247-265 Year: 2010
Safety and tolerability to long term moxifloxacin treatment in 38 patients with difficult to manage tuberculosis: preliminary data Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004